# Actinium-225

#### Nitrate (<sup>225</sup>Ac(NO<sub>3</sub>)<sub>3</sub>) in solid form

Method of production: Thorium-229 (Th-229) decay.

### Characteristic Nuclide Half-life **Decay Mode Maximum Alpha Energy Chemical form** Shelf-life

ART

#### Description

Ac-225 9.91 days Alpha/Beta Decay 5.935 MeV Ac<sup>3+</sup> nitrate in solid form Minimum of 15 days from date of manufacture. Note: Upon completion of stability studies, the final published shelf will be determined. Reference to 12:00 (EST) from 0-15 days after production.

Test	Specification
Appearance	Slight yellowish tinted, layered film
Radionuclidic Purity	- <sup>225</sup> Ra ≤ 0.02%, <sup>224</sup> Ra ≤ 0.02% - Sum activity of other isotopes ≤ 0.008%
Radiochemical Purity	$\geq$ 99.9% as <sup>225</sup> Ac(NO <sub>3</sub> ) <sub>3</sub>
Non-active impurities	. < 10 μg/mCi
Radionuclidic ID	- 218 keV gamma – daughter (Fr-221) major peak - 441 keV gamma – daughter (Bi-213) major peak or - 5935 KeV Alpha (Ac-225)
	Note: The specification will be based on the use of either gamma or alpha spectroscopy for the measurement.
Radiolabeling Yield	$\sim$ > 99.0% (based on radiolabeling with DOTA-derivate)

Vial Activity<sup>1</sup> Activity per Vial

## rement.

erivate)

0.1mCi - 5mCi at ART

90-110% of <sup>225</sup>Ac activity stated on label at ART

#### <sup>1</sup>Vial activity is variable and can be adjusted based upon order quantity.

Note: Actinium-225 is currently being validated for use as a cGMP product. This product has **not** necessarily received approval from all authorities depending on use. The product must be considered as a radiochemical limited to the claims made in the specifications. The company makes no product claims for use in clinical applications.

cGMP: Current Good Manufacturing Practices ART: Activity Reference Time or Calibration